{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-012898","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.322649+00:00","generated_at":"2026-06-04T02:51:51.066431+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Biotricity amends Series B Preferred Stock to remove voting rights; approved by holder","bullets":["Amended Certificate of Designations removes voting rights of Series B Preferred Stock (non-voting except as required by law).","Series B Preferred Stock: 600 shares designated at $10,000 stated value, cumulative 8% dividend (15% on Triggering Event).","Initial conversion price $3.50; alternate conversion at 80% of lowest VWAP (70% if delisted/reverse split).","Conversion capped at 4.99% beneficial ownership per holder and 19.9% of common stock absent shareholder approval.","Holder of outstanding Series B Preferred Stock approved amendment via written consent on April 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-012898","json":"https://secwatch.observer/filing/0001493152-24-012898.json","markdown":"https://secwatch.observer/filing/0001493152-24-012898.md","text":"https://secwatch.observer/filing/0001493152-24-012898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315224012898/0001493152-24-012898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315224012898/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:51:51.066431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89684a63ac05cdb5e915bc74d6d2c34d5108d143","claim":"BIOTRICITY INC.: Amended Certificate of Designations for Series B Convertible Preferred Stock to remove voting rights on an as-converted basis, making the shares non-voting except as required by law (effective 2024-04-01).","evidence_excerpt":"The Amended Certificate of Designations removes the provision in the original certificate of designations for the Series B Convertible Preferred Stock filed on September 19, 2023 that provided the holders of the Series B Preferred Stock with the right to vote on an as-converted basis with the Company’s common stock, subject to the beneficial ownership limitation set forth in the Certificate of Designations. The Amended Certificate of Designations provides that except as required by law, the Series B Preferred Stock is non-voting.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315224012898/0001493152-24-012898-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-04-01"}],"fact_type":"governance_change"},{"claim_id":"85210af9f5f48d3dd47ea682e7344c2d0c7d059e","claim":"BIOTRICITY INC. shareholders approved Approval of Amended Certificate of Designations for Series B Preferred Stock at the 2024-04-01 meeting.","evidence_excerpt":"the holder of the outstanding Seies B Preferred Stock approved the Amended Certificate of Designations via written consent","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315224012898/0001493152-24-012898-index.htm","confidence":0.4,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-01"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}